Skip to main content
. 2008 Oct 4;23(12):2095–2105. doi: 10.1007/s11606-008-0812-9

Table 5.

Reminder Plus Education With or Without Risk Assessment*

Study Intervention component (target of intervention) Outcomes Event rates (intervention vs. control) Relative risk† (95% CI)
Feldstein‡ (2006)34 Reminder (Phys & Pts) + Ed (Pts) BMD testing or initiation of OP medication 51% vs. 6% 8.67 (3.90 to 19.26)§∥
43% vs. 6% 7.26 (3.24 to 16.24)§∥
Gardner‡ (2005)35 Reminder (Phys & Pts) + Ed (Pts) OP addressed (BMD or OP therapy) 42% vs. 19% 2.14 (1.00 to 4.62)§∥
Solomon (2007)42 Reminder (Phys & Pts) + Ed (Phys, Pharmacists, & Pts) BMD testing 13% vs. 9% 1.43 (1.11 to 1.86)§∥
OP medication 6% vs. 4% 1.60 (1.07 to 2.41)§∥
McDonough (2005)37 Reminder (Phys) + Ed (Pharmacists & Pts) BMD testing 72% vs. 63% 1.14 (0.78 to 1.67)
Bisphosphonate therapy 26% vs. 10% 2.49 (0.63 to 9.87)
Calcium intake 56% vs. 32% 1.77 (0.88 to 3.55)
Solomon (2004)40 Reminder (Phys) + Ed (Phys) BMD testing 32% vs. 38% 0.84 (0.64 to 1.12)§
OP medications 8% vs. 8% 0.99 (0.49 to 2.00)§∥
Solomon (2006)41 Reminder (Pts) + Ed (Pts) BMD testing 46% vs. 42% 1.09 (0.91 to 1.30)∥
Calcium intake 68% vs. 69% 0.98 (0.89 to 1.09)∥
LaCroix (2005)36 Reminder (Phys & Pts) + Ed (Pts) + RA (SCORE) (Pts) Any fracture 9% vs. 12% 0.77 (0.52 to 1.12)
Initiation of any therapy 21% vs. 20% 1.05 (0.82 to 1.35)
Reminder (Phys & Pts) + Ed (Pts) + RA (SOF) (Pts) Any fracture 9% vs. 9% 0.96 (0.69 to 1.34)
Initiation of any therapy 21 vs. 17% 1.27 (1.03 to 1.56)§
Morrison (2004)38 Reminder (Phys) + Ed (Pts) + RA (Pts) Prescription of bisphosphonates Both groups increased in the prescription of bisphosphonates by 50% (p < 0.001), but no difference between groups for outcome

*CI = confidence interval; Phys = physician; Pts = patients; Ed = education; BMD = bone mineral density; OP = osteoporosis; RA = risk assessment; SCORE = simple calculated osteoporosis risk estimation; SOF = study of osteoporotic fracture

†Using random effects model, relative risk with 95% confidence intervals was calculated from event rates using Cochrane Review Manager 4.2.8

‡Study indicated all of: method of randomization sequence and concealment, blinding, follow-up, and ≥80% follow-up

§Significant

∥Data verified by author